Psy157 - Emerging Rheumatoid Arthritis and Psoriasis Biologics: How to Thrive in the Face of Biosimilar Competition?

Privolnev, Y.; Cox, J.; Reyes, Amy

doi:10.1016/j.jval.2018.09.2731

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It follows that the cost-effectiveness of biologic therapy can change through its lifecycle as a result of, for example, the market entry of biosimilars or of new innovative chemical or biologic medicines. This also implies that new innovative medicines which charge a premium price may struggle to be cost-effective and receive reimbursement when the therapeutic arsenal includes biosimilars of an earlier generation of biologic therapy [45,46].…”

Section: Economic Evaluation Of Biosimilarsmentioning

confidence: 99%

A health economic guide to market access of biosimilars

Simoens

Vulto

2021

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction:Little is known about market access to biosimilars from a health economic perspective, except for studies that compute the budget impact of biosimilar use.Areas covered: This comprehensive health economic guide to the market access of biosimilars focuses on the role of biosimilars in pharmaceutical innovation and competition, the objective of biopharmaceutical policy, the budget impact of biosimilars, and the cost-effectiveness of biologic therapy in the presence of biosimilars. Expert opinion: We argue that the objective of biopharmaceutical policy in a health system should be to create a competitive and sustainable market for off-patent reference biologics, biosimilars, and nextgeneration biologics that makes biologic therapy available to patients at the lowest cost. Market access of biosimilars can contribute to this objective as a result of the lower price of biosimilars and price competition with alternative therapies. The resulting improvement in the cost-effectiveness of biologic therapy needs to be accounted for by revisiting reimbursement decisions and conditions. When examining the cost-effectiveness of biologic therapy following patent expiry, stakeholders need to consider residual uncertainties at the time of biosimilar marketing authorization, the nocebo effect, market entry of a second-generation reference biologic with a different administration form than the biosimilar, and value-added services.

show abstract

Section: Economic Evaluation Of Biosimilarsmentioning

confidence: 99%